HIV Drug Pay-For-Delay Claims Too Speculative, Gilead Says
Gilead Sciences Inc. wants a California federal court to toss a proposed class action accusing the pharmaceutical company of paying off would-be generic competitors to its HIV drugs to delay market...To view the full article, register now.
Already a subscriber? Click here to view full article